25 XP   0   0   10

Mesoblast Ltd
Buy, Hold or Sell?

Let's analyse Mesoblast together

PenkeI guess you are interested in Mesoblast Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mesoblast Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mesoblast Ltd

I send you an email if I find something interesting about Mesoblast Ltd.

Quick analysis of Mesoblast (30 sec.)










What can you expect buying and holding a share of Mesoblast? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.49
Expected worth in 1 year
A$0.51
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$0.02
Return On Investment
2.5%

For what price can you sell your share?

Current Price per Share
A$0.77
Expected price per share
A$0.42007726527745 - A$1.0149500508741
How sure are you?
50%

1. Valuation of Mesoblast (5 min.)




Live pricePrice per Share (EOD)

A$0.77

Intrinsic Value Per Share

A$-0.68 - A$-0.49

Total Value Per Share

A$-0.19 - A$0.00

2. Growth of Mesoblast (5 min.)




Is Mesoblast growing?

Current yearPrevious yearGrowGrow %
How rich?$324.7m$321.6m$3.1m1.0%

How much money is Mesoblast making?

Current yearPrevious yearGrowGrow %
Making money-$52.9m-$59.1m$6.1m11.5%
Net Profit Margin-1,091.7%-894.6%--

How much money comes from the company's main activities?

3. Financial Health of Mesoblast (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#110 / 1019

Most Revenue
#328 / 1019

Most Profit
#954 / 1019

Most Efficient
#819 / 1019

What can you expect buying and holding a share of Mesoblast? (5 min.)

Welcome investor! Mesoblast's management wants to use your money to grow the business. In return you get a share of Mesoblast.

What can you expect buying and holding a share of Mesoblast?

First you should know what it really means to hold a share of Mesoblast. And how you can make/lose money.

Speculation

The Price per Share of Mesoblast is A$0.77. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mesoblast.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mesoblast, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.49. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mesoblast.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.05-6.8%-0.05-6.8%-0.06-7.6%-0.06-7.3%-0.05-6.0%
Usd Book Value Change Per Share0.000.4%0.000.4%-0.05-7.0%-0.01-0.7%-0.01-1.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.4%0.000.4%-0.05-7.0%-0.01-0.7%-0.01-1.1%
Usd Price Per Share0.77-0.77-0.42-1.15-1.45-
Price to Earnings Ratio-14.83--14.83--7.15--21.13--56.35-
Price-to-Total Gains Ratio253.40-253.40--7.74-67.68-20.82-
Price to Book Ratio2.42-2.42-1.31-3.40-4.14-
Price-to-Total Gains Ratio253.40-253.40--7.74-67.68-20.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.498344
Number of shares2006
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (2006 shares)6.13-11.30
Gains per Year (2006 shares)24.53-45.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1025150-45-55
2049400-90-100
3074650-136-145
4098900-181-190
501231150-226-235
601471400-271-280
701721650-316-325
801961900-362-370
902212150-407-415
1002452400-452-460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.018.00.05.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%11.08.00.057.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.019.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%11.08.00.057.9%

Fundamentals of Mesoblast

About Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-04-04 19:36:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Mesoblast Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mesoblast earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Net Profit Margin of -1,091.7% means that $-10.92 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mesoblast Ltd:

  • The MRQ is -1,091.7%. The company is making a huge loss. -2
  • The TTM is -1,091.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,091.7%TTM-1,091.7%0.0%
TTM-1,091.7%YOY-894.6%-197.1%
TTM-1,091.7%5Y-818.2%-273.5%
5Y-818.2%10Y-830.3%+12.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,091.7%-196.9%-894.8%
TTM-1,091.7%-211.2%-880.5%
YOY-894.6%-279.3%-615.3%
5Y-818.2%-436.8%-381.4%
10Y-830.3%-599.3%-231.0%
1.1.2. Return on Assets

Shows how efficient Mesoblast is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • -12.2% Return on Assets means that Mesoblast generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mesoblast Ltd:

  • The MRQ is -12.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.2%TTM-12.2%0.0%
TTM-12.2%YOY-13.8%+1.6%
TTM-12.2%5Y-12.7%+0.5%
5Y-12.7%10Y-10.2%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.2%-13.6%+1.4%
TTM-12.2%-12.9%+0.7%
YOY-13.8%-11.9%-1.9%
5Y-12.7%-14.2%+1.5%
10Y-10.2%-16.2%+6.0%
1.1.3. Return on Equity

Shows how efficient Mesoblast is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • -16.3% Return on Equity means Mesoblast generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mesoblast Ltd:

  • The MRQ is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-16.3%0.0%
TTM-16.3%YOY-18.4%+2.1%
TTM-16.3%5Y-16.9%+0.6%
5Y-16.9%10Y-14.0%-2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-17.0%+0.7%
TTM-16.3%-16.1%-0.2%
YOY-18.4%-15.4%-3.0%
5Y-16.9%-20.0%+3.1%
10Y-14.0%-21.1%+7.1%

1.2. Operating Efficiency of Mesoblast Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mesoblast is operating .

  • Measures how much profit Mesoblast makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • An Operating Margin of -921.7% means the company generated $-9.22  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mesoblast Ltd:

  • The MRQ is -921.7%. The company is operating very inefficient. -2
  • The TTM is -921.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-921.7%TTM-921.7%0.0%
TTM-921.7%YOY-792.8%-128.9%
TTM-921.7%5Y-791.8%-129.9%
5Y-791.8%10Y-903.3%+111.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-921.7%-282.4%-639.3%
TTM-921.7%-225.8%-695.9%
YOY-792.8%-288.4%-504.4%
5Y-791.8%-475.2%-316.6%
10Y-903.3%-624.7%-278.6%
1.2.2. Operating Ratio

Measures how efficient Mesoblast is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 17.56 means that the operating costs are $17.56 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mesoblast Ltd:

  • The MRQ is 17.559. The company is inefficient in keeping operating costs low. -1
  • The TTM is 17.559. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ17.559TTM17.5590.000
TTM17.559YOY15.117+2.443
TTM17.5595Y14.451+3.108
5Y14.45110Y13.582+0.870
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.5592.994+14.565
TTM17.5593.247+14.312
YOY15.1173.766+11.351
5Y14.4515.675+8.776
10Y13.5827.857+5.725

1.3. Liquidity of Mesoblast Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mesoblast is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.95 means the company has $1.95 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mesoblast Ltd:

  • The MRQ is 1.945. The company is able to pay all its short-term debts. +1
  • The TTM is 1.945. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.945TTM1.9450.000
TTM1.945YOY1.359+0.586
TTM1.9455Y1.560+0.385
5Y1.56010Y2.407-0.847
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9453.930-1.985
TTM1.9454.251-2.306
YOY1.3595.436-4.077
5Y1.5606.045-4.485
10Y2.4076.383-3.976
1.3.2. Quick Ratio

Measures if Mesoblast is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Quick Ratio of 1.86 means the company can pay off $1.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mesoblast Ltd:

  • The MRQ is 1.856. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.856. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.856TTM1.8560.000
TTM1.856YOY1.254+0.602
TTM1.8565Y1.459+0.397
5Y1.45910Y2.232-0.773
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8563.629-1.773
TTM1.8564.065-2.209
YOY1.2545.390-4.136
5Y1.4595.993-4.534
10Y2.2326.277-4.045

1.4. Solvency of Mesoblast Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mesoblast assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mesoblast to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Mesoblast assets are financed with 25.0% credit (debt) and the remaining percentage (100% - 25.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mesoblast Ltd:

  • The MRQ is 0.250. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.250. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.250TTM0.2500.000
TTM0.250YOY0.249+0.001
TTM0.2505Y0.246+0.004
5Y0.24610Y0.265-0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2500.332-0.082
TTM0.2500.333-0.083
YOY0.2490.268-0.019
5Y0.2460.366-0.120
10Y0.2650.390-0.125
1.4.2. Debt to Equity Ratio

Measures if Mesoblast is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mesoblast to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.4% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mesoblast Ltd:

  • The MRQ is 0.334. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.334. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.334TTM0.3340.000
TTM0.334YOY0.332+0.002
TTM0.3345Y0.328+0.006
5Y0.32810Y0.371-0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3340.380-0.046
TTM0.3340.389-0.055
YOY0.3320.334-0.002
5Y0.3280.432-0.104
10Y0.3710.465-0.094

2. Market Valuation of Mesoblast Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mesoblast generates.

  • Above 15 is considered overpriced but always compare Mesoblast to the Biotechnology industry mean.
  • A PE ratio of -14.83 means the investor is paying $-14.83 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mesoblast Ltd:

  • The EOD is -9.542. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.835. Based on the earnings, the company is expensive. -2
  • The TTM is -14.835. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.542MRQ-14.835+5.293
MRQ-14.835TTM-14.8350.000
TTM-14.835YOY-7.148-7.687
TTM-14.8355Y-21.128+6.293
5Y-21.12810Y-56.345+35.218
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.542-2.426-7.116
MRQ-14.835-2.552-12.283
TTM-14.835-2.656-12.179
YOY-7.148-4.143-3.005
5Y-21.128-6.252-14.876
10Y-56.345-6.108-50.237
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mesoblast Ltd:

  • The EOD is -12.289. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -19.106. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.106. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.289MRQ-19.106+6.817
MRQ-19.106TTM-19.1060.000
TTM-19.106YOY-9.891-9.215
TTM-19.1065Y-27.019+7.913
5Y-27.01910Y-26.462-0.556
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.289-3.199-9.090
MRQ-19.106-3.259-15.847
TTM-19.106-3.552-15.554
YOY-9.891-5.617-4.274
5Y-27.019-8.326-18.693
10Y-26.462-8.689-17.773
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mesoblast is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.42 means the investor is paying $2.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mesoblast Ltd:

  • The EOD is 1.557. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.421. Based on the equity, the company is underpriced. +1
  • The TTM is 2.421. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.557MRQ2.421-0.864
MRQ2.421TTM2.4210.000
TTM2.421YOY1.314+1.107
TTM2.4215Y3.399-0.978
5Y3.39910Y4.135-0.737
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5571.947-0.390
MRQ2.4212.116+0.305
TTM2.4212.095+0.326
YOY1.3142.836-1.522
5Y3.3993.443-0.044
10Y4.1353.791+0.344
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mesoblast Ltd.

3.1. Funds holding Mesoblast Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-10-31Vanguard International Stock Index-Total Intl Stock Indx1.13-7333452--
2020-12-31Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.49-3162015--
2021-02-28iShares Core MSCI EAFE ETF0.34-2192913--
2021-02-28iShares MSCI EAFE Small Cap ETF0.33000002-2139899--
2021-01-31DFA Asia Pacific Small Company Series0.23999999-1561474--
2020-10-31Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index0.2-1284383--
2021-02-28iShares Core MSCI Total International Stock ETF0.11-742482--
2020-11-30Schwab Strategic Tr-Schwab International Small Cap Equity ETF0.11-701021--
2020-12-31College Retirement Equities Fund-Stock Account0.07-473074--
2021-01-31Vanguard International Stock Index-Pacific Stock Index0.07-457924--
Total 3.0900000102004863700.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mesoblast Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0050.0050%-0.083+1860%-0.009+284%-0.013+368%
Book Value Per Share--0.4950.4950%0.490+1%0.515-4%0.530-7%
Current Ratio--1.9451.9450%1.359+43%1.560+25%2.407-19%
Debt To Asset Ratio--0.2500.2500%0.249+0%0.246+2%0.265-6%
Debt To Equity Ratio--0.3340.3340%0.332+1%0.328+2%0.371-10%
Dividend Per Share----0%-0%-0%-0%
Eps---0.081-0.0810%-0.090+12%-0.087+7%-0.072-11%
Free Cash Flow Per Share---0.063-0.0630%-0.065+4%-0.070+12%-0.085+35%
Free Cash Flow To Equity Per Share--0.0110.0110%-0.075+795%0.007+65%-0.022+300%
Gross Profit Margin--1.3391.3390%1.337+0%1.300+3%1.150+16%
Intrinsic Value_10Y_max---0.493--------
Intrinsic Value_10Y_min---0.683--------
Intrinsic Value_1Y_max---0.066--------
Intrinsic Value_1Y_min---0.081--------
Intrinsic Value_3Y_max---0.185--------
Intrinsic Value_3Y_min---0.235--------
Intrinsic Value_5Y_max---0.289--------
Intrinsic Value_5Y_min---0.376--------
Market Cap781396000.000-55%1214817080.0001214817080.0000%652922320.000+86%1808820112.000-33%2281361732.000-47%
Net Profit Margin---10.917-10.9170%-8.946-18%-8.182-25%-8.303-24%
Operating Margin---9.217-9.2170%-7.928-14%-7.918-14%-9.033-2%
Operating Ratio--17.55917.5590%15.117+16%14.451+22%13.582+29%
Pb Ratio1.557-55%2.4212.4210%1.314+84%3.399-29%4.135-41%
Pe Ratio-9.542+36%-14.835-14.8350%-7.148-52%-21.128+42%-56.345+280%
Price Per Share0.770-55%1.1971.1970%0.643+86%1.782-33%2.248-47%
Price To Free Cash Flow Ratio-12.289+36%-19.106-19.1060%-9.891-48%-27.019+41%-26.462+39%
Price To Total Gains Ratio162.995-55%253.404253.4040%-7.740+103%67.677+274%20.821+1117%
Quick Ratio--1.8561.8560%1.254+48%1.459+27%2.232-17%
Return On Assets---0.122-0.1220%-0.138+13%-0.127+4%-0.102-17%
Return On Equity---0.163-0.1630%-0.184+13%-0.169+4%-0.140-14%
Total Gains Per Share--0.0050.0050%-0.083+1860%-0.009+284%-0.013+368%
Usd Book Value--324789553.600324789553.6000%321686876.800+1%337923442.080-4%348366337.680-7%
Usd Book Value Change Per Share--0.0030.0030%-0.054+1860%-0.006+284%-0.008+368%
Usd Book Value Per Share--0.3200.3200%0.317+1%0.333-4%0.343-7%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.052-0.0520%-0.058+12%-0.056+7%-0.046-11%
Usd Free Cash Flow---41150917.600-41150917.6000%-42724260.800+4%-45900071.200+12%-55576487.840+35%
Usd Free Cash Flow Per Share---0.041-0.0410%-0.042+4%-0.045+12%-0.055+35%
Usd Free Cash Flow To Equity Per Share--0.0070.0070%-0.048+795%0.004+65%-0.014+300%
Usd Market Cap505719491.200-55%786229614.176786229614.1760%422571325.504+86%1170668376.486-33%1476497312.950-47%
Usd Price Per Share0.498-55%0.7750.7750%0.416+86%1.154-33%1.455-47%
Usd Profit---52998560.800-52998560.8000%-59119778.400+12%-56925899.840+7%-48950583.680-8%
Usd Revenue--4854647.2004854647.2000%6608559.200-27%9584514.240-49%12042774.000-60%
Usd Total Gains Per Share--0.0030.0030%-0.054+1860%-0.006+284%-0.008+368%
 EOD+2 -6MRQTTM+0 -0YOY+26 -85Y+20 -1410Y+15 -19

4.2. Fundamental Score

Let's check the fundamental score of Mesoblast Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.542
Price to Book Ratio (EOD)Between0-11.557
Net Profit Margin (MRQ)Greater than0-10.917
Operating Margin (MRQ)Greater than0-9.217
Quick Ratio (MRQ)Greater than11.856
Current Ratio (MRQ)Greater than11.945
Debt to Asset Ratio (MRQ)Less than10.250
Debt to Equity Ratio (MRQ)Less than10.334
Return on Equity (MRQ)Greater than0.15-0.163
Return on Assets (MRQ)Greater than0.05-0.122
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Mesoblast Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.036
Ma 20Greater thanMa 500.659
Ma 50Greater thanMa 1000.444
Ma 100Greater thanMa 2000.376
OpenGreater thanClose0.800
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets669,415
Total Liabilities167,577
Total Stockholder Equity501,838
 As reported
Total Liabilities 167,577
Total Stockholder Equity+ 501,838
Total Assets = 669,415

Assets

Total Assets669,415
Total Current Assets81,658
Long-term Assets587,757
Total Current Assets
Cash And Cash Equivalents 70,920
Net Receivables 6,998
Inventory -4,324
Other Current Assets 8,064
Total Current Assets  (as reported)81,658
Total Current Assets  (calculated)81,658
+/-0
Long-term Assets
Property Plant Equipment 6,491
Goodwill 134,453
Long Term Investments 1,757
Intangible Assets 442,730
Other Assets 2,326
Long-term Assets  (as reported)587,757
Long-term Assets  (calculated)587,757
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities41,982
Long-term Liabilities125,595
Total Stockholder Equity501,838
Total Current Liabilities
Short-term Debt 10,012
Short Long Term Debt 5,952
Accounts payable 20,145
Other Current Liabilities 5,426
Total Current Liabilities  (as reported)41,982
Total Current Liabilities  (calculated)41,535
+/- 447
Long-term Liabilities
Long term Debt Total 106,483
Other Liabilities 19,112
Long-term Liabilities  (as reported)125,595
Long-term Liabilities  (calculated)125,595
+/-0
Total Stockholder Equity
Common Stock1,249,123
Retained Earnings -820,805
Accumulated Other Comprehensive Income 73,520
Total Stockholder Equity (as reported)501,838
Total Stockholder Equity (calculated)501,838
+/-0
Other
Capital Stock1,249,123
Cash And Equivalents-2
Cash and Short Term Investments 70,920
Common Stock Shares Outstanding 739,040
Current Deferred Revenue6,399
Liabilities and Stockholders Equity 669,415
Net Debt 45,575
Net Invested Capital 610,601
Net Tangible Assets -75,345
Net Working Capital 39,676
Property Plant and Equipment Gross 28,472
Short Long Term Debt Total 116,495



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-30
> Total Assets 
21,466
16,385
21,238
27,789
26,975
39,515
763,251
720,456
883,712
899,314
1,017,925
684,018
655,686
692,443
652,115
733,602
744,717
662,142
669,415
669,415662,142744,717733,602652,115692,443655,686684,0181,017,925899,314883,712720,456763,25139,51526,97527,78921,23816,38521,466
   > Total Current Assets 
15,326
8,039
12,594
14,304
16,920
33,518
265,494
217,736
331,844
203,749
159,453
88,823
63,609
101,071
62,522
136,548
148,227
69,837
81,658
81,65869,837148,227136,54862,522101,07163,60988,823159,453203,749331,844217,736265,49433,51816,92014,30412,5948,03915,326
       Cash And Cash Equivalents 
15,094
7,855
12,055
14,094
16,526
32,049
263,228
206,749
315,309
196,394
144,142
80,937
45,761
37,763
50,426
129,328
136,881
60,034
70,920
70,92060,034136,881129,32850,42637,76345,76180,937144,142196,394315,309206,749263,22832,04916,52614,09412,0557,85515,094
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
250
250
0
0
0
0
0
00000250250000000000000
       Net Receivables 
201
88
510
124
305
1,376
2,101
10,669
12,063
6,098
5,172
4,054
3,493
50,116
4,060
1,574
4,842
4,403
6,998
6,9984,4034,8421,5744,06050,1163,4934,0545,1726,09812,06310,6692,1011,37630512451088201
       Other Current Assets 
32
97
29
86
89
93
166
319
4,472
1,257
10,139
3,832
14,355
13,192
8,286
5,898
6,756
5,400
8,064
8,0645,4006,7565,8988,28613,19214,3553,83210,1391,2574,472319166938986299732
   > Long-term Assets 
6,140
8,345
8,645
13,485
10,055
5,996
497,756
502,719
551,868
695,565
858,472
595,195
592,077
591,372
589,593
597,054
596,490
592,305
587,757
587,757592,305596,490597,054589,593591,372592,077595,195858,472695,565551,868502,719497,7565,99610,05513,4858,6458,3456,140
       Property Plant Equipment 
28
38
158
198
246
224
610
1,998
2,757
4,683
5,727
3,063
1,814
1,084
826
10,271
12,140
9,965
6,491
6,4919,96512,14010,2718261,0841,8143,0635,7274,6832,7571,9986102242461981583828
       Goodwill 
0
0
0
0
0
0
109,739
116,211
127,687
140,517
175,069
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453
134,453134,453134,453134,453134,453134,453134,453134,453175,069140,517127,687116,211109,739000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
2,300
1,966
1,997
2,321
2,317
1,871
2,080
1,758
1,757
1,7571,7582,0801,8712,3172,3211,9971,9662,3000000000000
       Intangible Assets 
705
806
818
526
482
439
365,587
381,008
420,147
547,387
671,599
453,370
451,897
450,153
448,673
447,148
446,093
444,199
442,730
442,730444,199446,093447,148448,673450,153451,897453,370671,599547,387420,147381,008365,587439482526818806705
       Other Assets 
0
0
0
0
0
0
21,820
3,502
1,277
2,978
2,367
2,343
1,916
3,361
3,324
3,311
1,724
1,930
2,326
2,3261,9301,7243,3113,3243,3611,9162,3432,3672,9781,2773,50221,820000000
> Total Liabilities 
2,203
4,419
699
1,573
1,185
1,596
247,406
241,608
253,446
327,596
408,566
155,857
138,920
146,435
171,063
184,276
163,320
165,098
167,577
167,577165,098163,320184,276171,063146,435138,920155,857408,566327,596253,446241,608247,4061,5961,1851,5736994,4192,203
   > Total Current Liabilities 
2,203
4,419
699
1,573
1,185
1,596
30,795
44,494
50,588
42,675
63,031
29,415
36,670
24,003
44,331
90,143
94,273
51,373
41,982
41,98251,37394,27390,14344,33124,00336,67029,41563,03142,67550,58844,49430,7951,5961,1851,5736994,4192,203
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
59,397
14,007
35,974
55,965
8,203
10,012
10,0128,20355,96535,97414,00759,3970000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
59,397
14,007
32,455
53,200
5,017
5,952
5,9525,01753,20032,45514,00759,3970000000000000
       Accounts payable 
206
2,240
458
1,429
1,042
1,072
3,038
11,573
20,780
20,723
28,242
27,155
21,805
18,921
13,060
24,972
19,598
23,079
20,145
20,14523,07919,59824,97213,06018,92121,80527,15528,24220,72320,78011,5733,0381,0721,0421,4294582,240206
       Other Current Liabilities 
1,997
2,179
241
144
143
524
627
4,712
13,632
6,024
6,720
2,260
14,865
5,082
17,264
65,171
74,675
2,185
5,426
5,4262,18574,67565,17117,2645,08214,8652,2606,7206,02413,6324,7126275241431442412,1791,997
   > Long-term Liabilities 
0
0
0
0
0
0
216,611
197,113
202,858
284,921
345,535
126,442
102,250
122,432
126,732
94,133
69,047
113,725
125,595
125,595113,72569,04794,133126,732122,432102,250126,442345,535284,921202,858197,113216,611000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
59,397
67,279
63,340
49,530
98,702
106,483
106,48398,70249,53063,34067,27959,3970000000000000
       Other Liabilities 
0
0
0
0
0
0
88,793
64,202
56,820
126,336
265,372
126,442
102,250
63,035
59,453
30,793
19,517
15,023
19,112
19,11215,02319,51730,79359,45363,035102,250126,442265,372126,33656,82064,20288,793000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
171,892
62,693
49,293
0
0
0
0
0
0
00000049,29362,693171,8920000000000
> Total Stockholder Equity
19,263
11,965
20,539
26,216
25,790
37,919
515,844
478,848
630,266
571,718
609,359
528,161
516,766
546,008
481,052
549,326
581,397
497,044
501,838
501,838497,044581,397549,326481,052546,008516,766528,161609,359571,718630,266478,848515,84437,91925,79026,21620,53911,96519,263
   Common Stock
20,668
20,668
37,422
51,019
62,460
87,949
477,115
485,004
654,458
677,087
737,260
770,272
830,425
889,481
910,405
1,051,450
1,163,153
1,165,309
1,249,123
1,249,1231,165,3091,163,1531,051,450910,405889,481830,425770,272737,260677,087654,458485,004477,11587,94962,46051,01937,42220,66820,668
   Retained Earnings 
-1,470
-9,769
-18,497
-28,559
-40,845
-55,626
34,981
-36,165
-97,827
-178,785
-298,153
-268,087
-344,902
-380,192
-469,991
-548,758
-647,569
-738,916
-820,805
-820,805-738,916-647,569-548,758-469,991-380,192-344,902-268,087-298,153-178,785-97,827-36,16534,981-55,626-40,845-28,559-18,497-9,769-1,470
   Accumulated Other Comprehensive Income 
-3
-13
-39
-102
-176
-271
-368
-658
-1,393
-2,337
-4,539
-5,083
-6,685
-7,516
40,638
46,634
65,813
70,651
73,520
73,52070,65165,81346,63440,638-7,516-6,685-5,083-4,539-2,337-1,393-658-368-271-176-102-39-13-3
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.